Putative Neuroprotective and Neurotoxic Kynurenine Pathway Metabolites Are Associated with Hippocampal and Amygdalar Volumes in Subjects with Major Depressive Disorder

[1]  P. Kochunov,et al.  Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. , 2014, JAMA psychiatry.

[2]  Steven C.R. Williams,et al.  Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugs—Linking Magnetic Resonance Imaging Findings to Cellular Pathology , 2014, Biological Psychiatry.

[3]  Ge Zhang,et al.  Epstein-Barr Virus Infection Induces Indoleamine 2,3-Dioxygenase Expression in Human Monocyte-Derived Macrophages through p38/Mitogen-Activated Protein Kinase and NF-κB Pathways: Impairment in T Cell Functions , 2014, Journal of Virology.

[4]  G. Lundkvist,et al.  Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. , 2013, Journal of psychiatric research.

[5]  Zhen Yan,et al.  The Ability of BDNF to Modify Neurogenesis and Depressive-Like Behaviors Is Dependent upon Phosphorylation of Tyrosine Residues 365/367 in the GABAA-Receptor γ2 Subunit , 2013, The Journal of Neuroscience.

[6]  R. Dantzer,et al.  NMDA Receptor Blockade by Ketamine Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior in C57BL/6J Mice , 2013, Neuropsychopharmacology.

[7]  Andrew H. Miller.  Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression , 2013, Neuropsychopharmacology.

[8]  B. McEwen,et al.  Dynamic plasticity: The role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors , 2013, Neuroscience.

[9]  S. Bilbo,et al.  Chemokines and the hippocampus: A new perspective on hippocampal plasticity and vulnerability , 2013, Brain, Behavior, and Immunity.

[10]  J. Szyndler,et al.  The kynurenine pathway: A missing piece in the puzzle of valproate action? , 2013, Neuroscience.

[11]  M. Landén,et al.  Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder , 2012, Bipolar disorders.

[12]  B. Bogerts,et al.  Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[13]  Shuxing Wang,et al.  Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. , 2012, The Journal of clinical investigation.

[14]  U. Grohmann,et al.  Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase , 2012, Molecular medicine.

[15]  M. Maes,et al.  Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways , 2012, BMC Medicine.

[16]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[17]  C. Pariante,et al.  Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis , 2012, Neuropsychopharmacology.

[18]  J. Kocki,et al.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio , 2012, Journal of Neural Transmission.

[19]  A. Eisch,et al.  The neurogenesis hypothesis of affective and anxiety disorders: Are we mistaking the scaffolding for the building? , 2012, Neuropharmacology.

[20]  H. Steinbusch,et al.  Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients , 2011, Brain, Behavior, and Immunity.

[21]  B. Bogerts,et al.  Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? , 2011, Journal of Neuroinflammation.

[22]  R. Schwarcz,et al.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. , 2011, Archives of general psychiatry.

[23]  B. Leonard,et al.  The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  R. Dantzer,et al.  Inflammation-associated depression: From serotonin to kynurenine , 2011, Psychoneuroendocrinology.

[25]  P. Barone,et al.  Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: Focus on individual differences , 2011, Pharmacology Biochemistry and Behavior.

[26]  Inbal Goshen,et al.  Immune modulation of learning, memory, neural plasticity and neurogenesis , 2011, Brain, Behavior, and Immunity.

[27]  J. Babb,et al.  The possible role of the kynurenine pathway in adolescent depression with melancholic features. , 2010, Journal of child psychology and psychiatry, and allied disciplines.

[28]  R. Schwarcz,et al.  Reduction of Endogenous Kynurenic Acid Formation Enhances Extracellular Glutamate, Hippocampal Plasticity, and Cognitive Behavior , 2010, Neuropsychopharmacology.

[29]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[30]  J. Price,et al.  Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication , 2010, NeuroImage.

[31]  Joost Janssen,et al.  Hippocampal volume change in schizophrenia. , 2010, The Journal of clinical psychiatry.

[32]  R. Dantzer,et al.  CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.

[33]  P. Koolschijn,et al.  Brain volume abnormalities in major depressive disorder: a Meta-analysis of magnetic resonance imaging studies , 2009, NeuroImage.

[34]  K. Larsson,et al.  Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[35]  R. Dantzer,et al.  Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice , 2009, Molecular Psychiatry.

[36]  W. Drevets,et al.  Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide , 2009, Neuroscience & Biobehavioral Reviews.

[37]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[38]  J. W. Rudy,et al.  Time course of hippocampal IL-1 β and memory consolidation impairments in aging rats following peripheral infection , 2009, Brain, Behavior, and Immunity.

[39]  I. Goshen,et al.  Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression , 2008, Molecular Psychiatry.

[40]  J. Koo,et al.  IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress , 2008, Proceedings of the National Academy of Sciences.

[41]  U. Grohmann,et al.  IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation , 2007, Nature Reviews Immunology.

[42]  Fred H. Gage,et al.  An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus , 2007, Proceedings of the National Academy of Sciences.

[43]  H. Steinbusch,et al.  Kynurenine pathway in major depression: evidence of impaired neuroprotection. , 2007, Journal of affective disorders.

[44]  R. Coimbra,et al.  Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury , 2006, Neurobiology of Disease.

[45]  E. Irle,et al.  Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. , 2004, The American journal of psychiatry.

[46]  James C. Overholser,et al.  Cellular changes in the postmortem hippocampus in major depression , 2004, Biological Psychiatry.

[47]  P. L. Le Roux,et al.  Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: Involvement of NMDA receptors , 2003, Journal of neuroscience research.

[48]  C. Nemeroff,et al.  Interferon-alpha–induced changes in tryptophan metabolism relationship to depression and paroxetine treatment , 2003, Biological Psychiatry.

[49]  Marianna D. Eddy,et al.  Regionally localized thinning of the cerebral cortex in schizophrenia , 2003, Schizophrenia Research.

[50]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[51]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[52]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[53]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[54]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[55]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[56]  T. Stone,et al.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid , 1982, Brain Research.

[57]  Andrew H. Miller,et al.  Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior , 2012, Neuropsychopharmacology.

[58]  B. Bogerts,et al.  Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. , 2008, Journal of psychiatric research.

[59]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[60]  D. Keskin,et al.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells , 2002 .